Clinical trials: Benign Hyperplasia of Prostate
Prostatic Hyperplasia
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
The objective of the observational study were to investigate the switch from phytotherapy to ALNA® after at least 4 weeks of phytotherapy and still presented with a symptom sum score of ≥ 8 points (International Prostate Symptom…
- Trial name
- NCT02244320
- Testing
- Tamsulosin
- Volunteers
- 4,150 people
- Sponsor
- Boehringer Ingelheim
Lower Urinary Tract Symptoms
Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH
The purpose of the this international, multicenter, randomised, single-blind, parallel group, Phase III study is to demonstrate that a single transrectal ultrasound (TRUS)-guided intraprostatic injection of NX-1207 provides a…
- Trial name
- NCT02003742
- Testing
- NX-1207, Tamsulosin
- Where
- 5 sites in Germany, Italy and 3 more
- Volunteers
- 104 people
- Sponsor
- RECORDATI GROUP
Prostatic Hyperplasia
Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)
Study to evaluate the safety profile of Secotex® in the improvement of the symptoms of Benign Prostatic Hyperplasia in real clinical practice
- Trial name
- NCT02244346
- Testing
- Secotex®
- Volunteers
- 811 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hypertrophy
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH) is the most common hyperplastic disease occuring in human males over the age of 50 which increases in prevalence with age and 40% of males reported moderate or severe urinary symptoms of…
- Trial name
- AEZS-102-Z041 (NCT00670306)
- Testing
- Cetrorelix Pamoate
- Where
- 69 sites in United States, Canada
- Volunteers
- 528 people
- Sponsor
- AEterna Zentaris
Benign Prostatic Hyperplasia
Once Daily Given Alfuzosin in the Treatment of BPH
Collection of the data on the safety and efficacy of the once daily administration of the alfuzosin preparation /Alfetim Uno® l0 mg/ at patients with lower urinary tract symptoms/complaints rendering possible the presence of…
- Trial name
- NCT00637715
- Testing
- Alfuzosin
- Where
- Hungary
- Volunteers
- 60 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.
- Trial name
- NCT00127179
- Testing
- MK0906, finasteride / Duration of Treatment: 48 weeks
- Volunteers
- 600 people
- Sponsor
- Organon and Co
Benign Prostatic Hyperplasia
The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score
Primary: Evaluate the safety and onset of symptom relief using an acute I-PSS form (7 day form). Determine onset of urinary peak flow improvement after 7 days Secondary: Determine improvement in Bother Score after 7 \& 28 days…
- Trial name
- ALF-ACUTE (NCT00540891)
- Testing
- ALFUZOSIN
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
A Study in Benign Prostatic Hyperplasia
The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured…
- Trial name
- NCT01152190
- Testing
- Tadalafil
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hypertrophy
Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH
Korea has newly adopted 8mg Silodosin once daily. Against these backdrops, this clinical study is designed to demonstrate that the newly adopted dose is not inferior to the existing dose in its efficacy and safety.
- Trial name
- NCT01260129
- Testing
- Silodosin
- Where
- 14 sites in South Korea
- Volunteers
- 424 people
- Sponsor
- JW Pharmaceutical
Benign Prostatic Hyperplasia
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the safety and efficacy of various fixed daily doses of WC3055 compared with placebo for the treatment of subjects with LUTS secondary to BPH.
- Trial name
- NCT01939184
- Testing
- WC3055
- Where
- 95 sites in United States
- Volunteers
- 796 people
- Sponsor
- Warner Chilcott
Benign Prostatic Hyperplasia (BPH)
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
This clinical trial is designed as a randomized, placebo-controlled, single-blind, parallel design, multi-center, phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia.
- Trial name
- NCT02855892
- Testing
- GV1001
- Where
- 8 sites in South Korea
- Volunteers
- 161 people
- Sponsor
- GemVax & Kael
Benign Prostatic Hyperplasia (BPH), Overactive Bladder
A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.
To evaluate the influence of BR9006-1 and BR9006-2 on pharmacokinetics, safety, and tolerability when administered separately or co-administered to healthy male volunteers.
- Trial name
- NCT04485585
- Testing
- BR9006-1, BR9006-2
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Benign Prostatic Hyperplasia, Prostate Cancer
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
Dutasteride is used in the treatment of benign prostate enlargement (BPH).It inhibits conversion of testosterone (T) into the more potent dihydrotestosterone (DHT) to stop prostate (and possibly prostate cancer) growth.
- Trial name
- NCT00375765
- Testing
- Dutasteride
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)
This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.
- Trial name
- NCT01003886
- Testing
- Doxazosin mesylate GITS
- Where
- 67 sites in Philippines
- Volunteers
- 989 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Benign Prostatic Hyperplasia
Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath
To demonstrate the safety and efficacy of the Urocross Expander System/Retrieval Sheath and the procedure to treat patients with symptomatic Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT05400980
- Testing
- Urocross implant
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- Prodeon Medical, Inc
Benign Prostatic Hyperplasia
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single treatment of PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH) as compared to placebo.
- Trial name
- NCT01454349
- Testing
- PRX302
- Where
- 15 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sophiris Bio Corp
Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
The Efficacy and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia
Objective: To evaluate the efficacy and safety of Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release…
- Trial name
- NCT05551221
- Testing
- Silodosin Capsules, Tamsulosin
- Where
- 8 sites in China
- Volunteers
- 110 people
- Sponsor
- Xintian Pharmaceutical
Benign Prostatic Hyperplasia (BPH)
Study to Assess the Efficacy of Medi-Tate iTind Device
The study will include an implantation of the iTind device and 4 follow up visits up to 12 months after the implantation.
- Trial name
- NCT02145208
- Testing
- TIND System
- Where
- 8 sites in Belgium, Italy and 3 more
- Volunteers
- 81 people
- Sponsor
- Medi-Tate Ltd.
Lower Urinary Tract Symptoms, Prostatic Hyperplasia
A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH
The study will examine the efficacy,safety and tolerability of combination therapy of tamsulosin and solifenacin compared to placebo and monotherapy of tamsulosin and solifenacin in the treatment of males with LUTS associated…
- Trial name
- SATURN (NCT00510406)
- Testing
- tamsulosin hydrochloride, solifenacin succinate
- Where
- 98 sites in Austria, Czechia and 14 more
- Volunteers
- 919 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia
Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia
This is a prospective, randomized, open-label, parallel-group, medication-control, superiority, multicenter clinical study trial.
- Trial name
- NCT05531344
- Testing
- Composite Steep-pulse Treatment Device, Tamsulosin Hydrochloride Capsules
- Where
- China
- Volunteers
- 160 people
- Sponsor
- REMD Medical Technology